etoposide has been researched along with Prostatic Neoplasms, Castration-Resistant in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alabi, BR; Liu, S; Stoyanova, T | 1 |
| Hwang, SY; Jeon, KH; Jo, H; Jung, AR; Kwon, Y; Na, Y; Park, S; Seo, SH; Shin, JH | 1 |
| Barboro, P; Boccardo, F; Capaia, M; Cattrini, C | 1 |
| Erdelkamp, R; Hentrich, M; Stief, C; Tritschler, S | 1 |
| Asprino, PF; Bastos, DA; Bezerra, ROF; Camargo, AA; Canedo, FSNA; de Melo, ALA; Gongora, ABL | 1 |
| Aimono, E; Hongo, H; Kosaka, T; Mikami, S; Nishihara, H; Oya, M; Watanabe, K | 1 |
| Bompas, E; Clarisse, B; Cojocarasu, O; Delva, R; Eymard, JC; Guillot, A; Houede, N; Joly, F; Leconte, A; Lheureux, S; Linassier, C; Mourey, L; Oudard, S; Ravaud, A; Ringensen, F; Sevin, E; Tubiana-Mathieu, N; Valenza, B; Vedrine, L | 1 |
| Furuse, H; Ishii, Y; Kai, F; Nagata, M; Otsuka, A; Ozono, S; Sugiyama, T; Suzuki, T; Takayama, T; Yajima, T | 1 |
| Aieta, M; Bosso, D; Buonerba, C; Cobelli, OD; De Placido, S; Di Lorenzo, G; Federico, P; Ferro, M; Imbimbo, C; Izzo, M; Longo, N; Perri, F; Policastro, T; Puglia, L; Vittoria Scarpati, GD | 1 |
| Ajiboye, AS; Antonarakis, ES; Cao, H; Carducci, MA; Denmeade, SR; Eisenberger, MA; Haffner, MC; Isaacs, JT; Luo, J; Schweizer, MT; Spitz, A; Wang, H; Yegnasubramanian, S | 1 |
1 review(s) available for etoposide and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Current and emerging therapies for neuroendocrine prostate cancer.
Topics: Carcinoma, Neuroendocrine; Etoposide; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2022 |
3 trial(s) available for etoposide and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Etoposide; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Palliative Care; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Vinblastine; Vinorelbine | 2015 |
Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Humans; Male; Neoplasm Grading; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2014 |
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.
Topics: Aged; Aged, 80 and over; Androgens; Cell Line, Tumor; Cell Proliferation; Etoposide; Humans; Male; Middle Aged; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiography; Receptors, Androgen; Treatment Outcome | 2015 |
6 other study(ies) available for etoposide and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Synthesis and evaluation of 7-(3-aminopropyloxy)-substituted flavone analogue as a topoisomerase IIα catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells.
Topics: Androgen Antagonists; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Flavones; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2023 |
Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Etoposide; Humans; Male; Organophosphorus Compounds; Prostatic Neoplasms, Castration-Resistant; Topoisomerase II Inhibitors | 2020 |
[Neuroendocrine prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chromogranin A; Cisplatin; Etoposide; Humans; Male; Neoplasms, Second Primary; Neuroendocrine Tumors; Phosphopyruvate Hydratase; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2017 |
Tumor Lysis Syndrome After Platinum-based Chemotherapy in Castration-resistant Prostate Cancer With a BRCA2 Mutation: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Carboplatin; Etoposide; Humans; Male; Middle Aged; Mutation; Prognosis; Prostatic Neoplasms, Castration-Resistant; Tumor Lysis Syndrome | 2019 |
Japanese Case of Enzalutamide-Resistant Prostate Cancer Harboring a SPOP Mutation With Scattered Allelic Imbalance: Response to Platinum-Based Therapy.
Topics: Aged; Allelic Imbalance; Benzamides; Carboplatin; Drug Resistance, Neoplasm; Etoposide; Humans; Japan; Male; Mutation; Nitriles; Nuclear Proteins; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Repressor Proteins; Treatment Outcome | 2019 |
[Salvage therapy for castration-refractory prostate cancer resistant to docetaxel].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Etoposide; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Streptonigrin; Taxoids; Tegafur; Uracil | 2013 |